High-Dose antifungal drug tested against deadly zygomycosis
NCT ID NCT00467883
First seen Mar 07, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This Phase 2 trial tested a high dose (10 mg/kg/day) of the antifungal drug liposomal amphotericin B (Ambisome) in 40 people with zygomycosis, a rare but serious fungal infection. The goal was to see if the high dose could effectively control the infection after 4 weeks of treatment. Researchers measured complete or partial response to treatment, as well as safety and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ZYGOMYCOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hôpital Necker - Service des Maladies Infectieuses et Tropicales
Paris, 75015, France
-
Necker Hospital
Paris, 75015, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
liposomal amphotericin B (Ambisome)
What this could lead to
If successful, this could provide a more effective treatment option for zygomycosis, a serious fungal infection.
What could go wrong
This is a small Phase 2 trial with only 40 participants, so results may not apply broadly. High doses of Ambisome can cause kidney problems and other side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.